Our results show that 3 is a dual-targeting AChE and MAO-B inhibitor, 4 is an AChE inhibitor, and 5 is a MAO-B inhibitor, and suggest the potential use of these compounds for the treatment of AD. This evidence concerns the gene MAOB and Alzheimer disease.